IL108784A0 - Use of 2h-1,2,4-benzothiadiazin-3(4h)-one 1,1-dioxide derivatives as noncompetitive antagonists of the mmda receptor - Google Patents

Use of 2h-1,2,4-benzothiadiazin-3(4h)-one 1,1-dioxide derivatives as noncompetitive antagonists of the mmda receptor

Info

Publication number
IL108784A0
IL108784A0 IL10878494A IL10878494A IL108784A0 IL 108784 A0 IL108784 A0 IL 108784A0 IL 10878494 A IL10878494 A IL 10878494A IL 10878494 A IL10878494 A IL 10878494A IL 108784 A0 IL108784 A0 IL 108784A0
Authority
IL
Israel
Prior art keywords
benzothiadiazin
dioxide derivatives
noncompetitive antagonists
mmda
receptor
Prior art date
Application number
IL10878494A
Other languages
English (en)
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of IL108784A0 publication Critical patent/IL108784A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
IL10878494A 1993-03-03 1994-02-28 Use of 2h-1,2,4-benzothiadiazin-3(4h)-one 1,1-dioxide derivatives as noncompetitive antagonists of the mmda receptor IL108784A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9302439A FR2702150B1 (fr) 1993-03-03 1993-03-03 Application de dérivés de 2H-1,2-4-benzothiadiazine-3(4H)-one-1,1-dioxyde comme antagonistes non compétitifs du récepteur NMDA.

Publications (1)

Publication Number Publication Date
IL108784A0 true IL108784A0 (en) 1994-06-24

Family

ID=9444603

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10878494A IL108784A0 (en) 1993-03-03 1994-02-28 Use of 2h-1,2,4-benzothiadiazin-3(4h)-one 1,1-dioxide derivatives as noncompetitive antagonists of the mmda receptor

Country Status (10)

Country Link
EP (1) EP0687178A1 (xx)
JP (1) JPH08507303A (xx)
AU (1) AU6143694A (xx)
CA (1) CA2153951A1 (xx)
FR (1) FR2702150B1 (xx)
HU (1) HU9502572D0 (xx)
IL (1) IL108784A0 (xx)
NO (1) NO953387L (xx)
PL (1) PL310439A1 (xx)
WO (1) WO1994020109A1 (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
SI2091948T1 (sl) 2006-11-30 2012-07-31 Probiodrug Ag Novi inhibitorji glutaminil ciklaze
ZA200905537B (en) 2007-03-01 2010-10-27 Probiodrug Ag New use of glutaminyl cyclase inhibitors
EP2142514B1 (en) 2007-04-18 2014-12-24 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
ES2548913T3 (es) 2009-09-11 2015-10-21 Probiodrug Ag Derivados heterocíclicos como inhibidores de glutaminil ciclasa
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
JP5688745B2 (ja) 2010-03-10 2015-03-25 プロビオドルグ エージー グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB975925A (en) * 1961-02-21 1964-11-25 Scherico Ltd 3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxides
US4716161A (en) * 1984-04-17 1987-12-29 Mitsubishi Chemical Industries Limited Phenylpiperazine derivatives and their acid addition salts
FR2675801A1 (fr) * 1991-04-24 1992-10-30 Rhone Poulenc Rorer Sa Piperidines, leur preparation et les medicaments les contenant.
WO1993021170A1 (fr) * 1992-04-15 1993-10-28 Rhone-Poulenc Rorer S.A. Derives d'acide 3,4-dihydro-2h-1,2,4-benzothiadiazine 1,1-dioxyde-3-carboxylique, leur preparation et les medicaments les contenant
FR2690160A1 (fr) * 1992-04-15 1993-10-22 Rhone Poulenc Rorer Sa Application de dérivés d'acide 2H-1,2,4-benzothiadiazine-1,1-dioxyde-3-carboxylique à la préparation de médicaments, les produits nouveaux, leur préparation et les médicaments les contenant.

Also Published As

Publication number Publication date
NO953387D0 (no) 1995-08-29
FR2702150B1 (fr) 1995-04-07
PL310439A1 (en) 1995-12-11
CA2153951A1 (fr) 1994-09-15
WO1994020109A1 (fr) 1994-09-15
NO953387L (no) 1995-08-29
HU9502572D0 (en) 1995-11-28
EP0687178A1 (fr) 1995-12-20
AU6143694A (en) 1994-09-26
FR2702150A1 (fr) 1994-09-09
JPH08507303A (ja) 1996-08-06

Similar Documents

Publication Publication Date Title
HUP9902056A3 (en) Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
IL133604A0 (en) Fused 1, 2, 4-thiadiazine derivatives, their preparation and use
HUP0104646A3 (en) Fused 1,2,4-thiadiazine derivatives, their preparation and use
HU9502978D0 (en) 1,5-benzodiazepine derivatives cck antagonistic or agonistic activity
GR3030668T3 (en) Condensed indole derivatives as 5ht 4?-receptor antagonists.
HUP0102470A3 (en) 1,3-azole derivatives as retinoid-associated receptor regulators and their use
HK1016165A1 (en) 5-Phenyl-3-(peperidin-4-yl)-1,3,4-oxadiazol-2(3h)-one derivatives for use as 5-ht4 or h3 receptor ligands
EP0707581A1 (en) INDOLINE DERIVATIVES AS 5 HT2C ANTAGONISTS
WO2000012623A3 (en) Use of 5-th receptor antagonists for the treatment of parkinson's disease
IL108784A0 (en) Use of 2h-1,2,4-benzothiadiazin-3(4h)-one 1,1-dioxide derivatives as noncompetitive antagonists of the mmda receptor
HUP9904032A3 (en) 1,2,4-benzothiadiazine derivatives,their preparation and use
GB9217475D0 (en) Nauroprotective use cck antagonists
HU9600124D0 (en) 1,5-benzodiazepine derivatives useful as cck or gastrin antagonists
EP0681583A1 (en) TRICYCLIC HETEROCYCLIC COMPOUNDS AS 5-HT4 RECEPTOR ANTAGONISTS.
ZA891799B (en) New 3,4,5-substituted 4h-1,2,4-triazoles,the preparation and use thereof
AU4282993A (en) Benzothiazepine and benzoxazepine derivatives as cholecystokinin receptor antagonists
ZA894097B (en) Alpha-adrenergic receptor antagonists
GB2270313B (en) 1,3,4-Benzotriazepin-5 (4H)-one derivatives and process for the preparation thereof
NZ300041A (en) 2-(2,3,5,6-tetrafluoropyridin-4-yl)-1,2,5-thiazolidin-3-one 1,1-dioxide derivatives
IL122542A0 (en) Spiro Ú2h-1-benzopyran-2,4'-piperidine¾-4(3h)-one derivatives and pharmaceutical compositions containing them
IL109521A (en) 1,3-Di-substituted 8-tetrahydro-2-naphthyl xanthines as selective adnenosine receptor agents
GR3035910T3 (en) Derivatives of 10,11-dihydro-10-oxo-5h-dibenz/b,f/azepine-5-carboxamide
ZA9811651B (en) 1,2,4-Benzothiadiazine derivatives their preparation and use
AU7228994A (en) 1,5-benzodiazepine derivatives useful as cck or gastrin antagonists
ZA9811647B (en) Fused 1,2,4-thiadiazine derivatives their preparation and use